RxDoctor Payments DataLook up a doctor →

Elie Chalhoub, MD

Internal Medicine · Bemidji, MNNPI 1336451665

Payments from drug & device makers

$62,578in general payments, 2019–2025

Across 332 payments — averaging $188.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$55K
  • Janssen Global Services, LLC$2K
  • AstraZeneca$562
  • Novartis$558
  • Pfizer$297
  • Daiichi Sankyo Inc.$281
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$1,76022%
  • Food & beverage$6,25278%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck11$54,603
Janssen Global Services, LLC1$1,760
AstraZeneca(2 entities)28$562
Novartis30$558
Pfizer22$297
Daiichi Sankyo Inc.13$281
E.r. Squibb & Sons, L.L.C.18$242
Johnson & Johnson(2 entities)11$233
Eisai Inc.10$192
Apellis Pharmaceuticals, Inc.6$150
EMD Serono, Inc.8$148
Deciphera Pharmaceuticals Inc.7$146
GSK7$143
Gilead8$139
Takeda Pharmaceuticals U.S.A., Inc.5$134
AVEO Pharmaceuticals, Inc.5$133
Sanofi7$130
Bristol Myers Squibb7$128
Servier Pharmaceuticals LLC6$124
Genentech USA, Inc.7$114
Ipsen Biopharmaceuticals, Inc5$111
Tersera Therapeutics LLC4$111
Exelixis Inc.5$109
Pharmacosmos Therapeutics Inc.5$103
Genmab U.S., Inc.5$98
ADC Therapeutics America, Inc.5$94
Stemline Therapeutics Inc.5$91
Spectrum Pharmaceuticals Inc.5$91
AbbVie4$86
Array Biopharma Inc5$81
Kyowa Kirin, Inc.4$79
Jazz Pharmaceuticals Inc.3$76
Sumitomo Pharma America, Inc.4$76
Blue Earth Diagnostics3$63
Bayer3$57
Rigel Pharmaceuticals, Inc.3$56
Astellas Pharma US Inc3$56
Lilly USA, LLC3$53
Regeneron Healthcare Solutions, Inc.2$50
Mirati Therapeutics, Inc.2$50
Adaptive Biotechnologies Corporation2$49
Incyte Corporation2$48
Acrotech Biopharma Inc.2$47
Dendreon Pharmaceuticals LLC2$44
Octapharma USA, Inc.2$43
Coherus Oncology, Inc.2$40
Avyxa Pharma, LLC2$38
Syndax Pharmaceuticals, Inc.2$36
Amgen2$34
Seagen Inc.2$33
Blueprint Medicines Corporation2$33
Tempus AI, Inc1$28
Azurity Pharmaceuticals, Inc.1$27
Myriad Genetic Laboratories, Inc.1$26
Legend Biotech USA Inc.1$25
Geron Corporation1$25
Recordati_rare_diseases_inc.1$25
Pharmaessentia USA Corporation1$23
Caris MPI, Inc.1$21
Immunocore Limited1$21

How this compares

$62,578 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$9,105,576
Medicare patients
1,219
Services billed
381,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide18$389,903
PomalystPomalidomide12$282,835
ImbruvicaIbrutinib15$244,901
CalquenceAcalabrutinib Maleate17$244,406
Lenalidomide13$219,505
Abiraterone Acetate28$91,713
EliquisApixaban59$42,338
Imatinib Mesylate12$36,409
Deferasirox15$6,628
Letrozole206$4,043
Potassium Chloride54$1,089
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$933
Anastrozole68$875
Dexamethasone59$726
Hydroxyurea38$683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$128$389,90318 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$242$282,83512 claims
AstraZenecaCalquence$562$244,40617 claims
PfizerEliquis$297$42,33859 claims
Lilly USA, LLCOlanzapine$53$8611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →